Aldeyra Therapeutics Achieves Primary Endpoints in Dry Eye Disease Chamber Crossover Clinical Trial
· Issued by Aldeyra Therapeutics, Inc.
-
Reproxalap Statistically Superior to Vehicle for Both Primary Endpoints of Ocular Redness (P=0.0004) and Schirmer Test (P=0.0005)
-
Schirmer Test ≥10mm Responder Analysis Multiplicity-Controlled Secondary Endpoint Achieved (P=0.0361)
-
Secondary Endpoints Achieved for All Symptoms Assessed: Dryness (P=0.0068), Discomfort (P
Aldeyra Therapeutics, Inc. on 6ix
